Zoetis Inc. (NYSE:ZTS) Shares Bought by Security National Bank

Security National Bank grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% in the first quarter, HoldingsChannel reports. The fund owned 47,467 shares of the company’s stock after buying an additional 609 shares during the quarter. Zoetis makes up about 1.2% of Security National Bank’s portfolio, making the stock its 19th largest position. Security National Bank’s holdings in Zoetis were worth $8,032,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Norges Bank purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $980,646,000. Price T Rowe Associates Inc. MD raised its stake in shares of Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in Zoetis in the 4th quarter valued at about $242,757,000. CIBC Private Wealth Group LLC lifted its stake in shares of Zoetis by 122.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock worth $285,923,000 after acquiring an additional 797,884 shares during the period. Finally, Corient Private Wealth LLC increased its stake in shares of Zoetis by 44.4% during the fourth quarter. Corient Private Wealth LLC now owns 1,953,508 shares of the company’s stock valued at $385,564,000 after acquiring an additional 600,804 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 1.9 %

ZTS traded up $3.11 during trading on Wednesday, reaching $171.09. The company had a trading volume of 1,327,929 shares, compared to its average volume of 2,944,039. The company has a market cap of $78.07 billion, a P/E ratio of 32.47, a PEG ratio of 2.61 and a beta of 0.88. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. The business’s fifty day moving average price is $167.30 and its 200 day moving average price is $179.00.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter last year, the firm earned $1.31 earnings per share. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a yield of 1.01%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on ZTS. HSBC cut their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. The Goldman Sachs Group reduced their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Finally, Barclays lowered their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average price target of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.